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Article Summary for Table of Contents: 28 
Intestinal helminth infection increases small intestinal colonization by Salmonella, which occurs 29 
independently of the induction of T regulatory or Th2 cells following helminth infection. 30 
Helminth infection disrupts the intestinal metabolome, and the resulting shift in metabolites 31 
directly enhances Salmonella virulence.  32 
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Abstract: Intestinal helminth infections occur predominantly in regions where exposure to 33 
enteric bacterial pathogens is also common. Helminth infections inhibit host immunity against 34 
microbial pathogens, which has largely been attributed to the induction of regulatory or type 2 35 
(Th2) immune responses. Here we demonstrate an additional three-way interaction in which 36 
helminth infection alters the metabolic environment of the host intestine to enhance bacterial 37 
pathogenicity. We show that an ongoing helminth infection increased colonization by Salmonella 38 
independently of T regulatory or Th2 cells. Instead, helminth infection altered the metabolic 39 
profile of the intestine, which directly enhanced bacterial expression of Salmonella pathogenicity 40 
island 1 (SPI-1) genes and increased intracellular invasion. These data reveal a novel mechanism 41 
by which a helminth-modified metabolome promotes susceptibility to bacterial co-infection. 42 
Word count: 123 43 
 44 
Keywords: co-infection; immunomodulation; parasites; helminths; bacterial infection; intestinal 45 
metabolites 46 
 47 
  48 
 4 
Background: 49 
Chronic helminth infections occur predominantly in regions of poor sanitation, where the risk of 50 
co-infection with microbial pathogens is high [1]. Ongoing helminth infections have been 51 
associated with increased susceptibility to secondary microbial infections in mice and people. In 52 
mice, helminths impair host resistance to Citrobacter rodentium, Salmonella enterica serovar 53 
Typhimurium, Escherichia coli strain UTI89 (UPEC), norovirus and y-herpesvirus [2–6]. In 54 
humans, helminth infections correlate with increased severity of tuberculosis, higher 55 
Plasmodium burdens during malaria, impaired immunity to Vibrio cholerae, and greater 56 
incidence of human immunodeficiency virus (HIV) infection [7–12]. 57 
It is currently thought that helminth mediated immunomodulation underpins increased 58 
susceptibility to secondary microbial infections. Helminth infections characteristically induce a 59 
robust T helper (Th)2 immune response, marked by the cytokines IL-4, IL-5 and IL-13, and a 60 
strong regulatory T cell (Treg) response [13]. Both Th2 and Treg responses have been proposed 61 
to impair the generation of protective Th1 or Th17 immunity against bacterial or viral pathogens 62 
[2–5,14–16]. In this regard, widespread IL-4 signaling during helminth infection can impair the 63 
production of antimicrobial IFN-γ from CD4+ T cells and invariant natural killer T cells [2,5,17], 64 
and helminth-elicited IL-4 and IL-10 can block effector differentiation of CD8+ T cells after 65 
challenge with irradiated Toxoplasma gondii parasites [16]. Moreover, Th2 cytokines can 66 
directly promote viral replication: IL-4 switches on signal transducer and activator of 67 
transcription 6 (Stat6) which binds to and activates γ-herpes viral promotors controlling latent-68 
lytic switch genes [4]. Alongside Th2 cytokines, Tregs can impede antimicrobial immunity 69 
through the suppression of effector T cell responses [14,15]. In this manner, helminth-induced 70 
Tregs can also reduce inflammation during allergic airway inflammation and graft versus host 71 
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disease [18–20]. Thus, direct modulation of host immunity is one pathway by which helminths 72 
facilitate secondary microbial infections. 73 
Here, we use a mouse model of co-infection to identify an additional mechanism by which 74 
intestinal helminths alter host immunity to concurrent bacterial pathogens. We show that the 75 
greater susceptibility of helminth-infected mice to the bacterial pathogen S. Typhimurium occurs 76 
independently of the induction of Treg or Th2 cells following helminth infection. Instead, we 77 
reveal a previously unidentified pathway of inter-kingdom interaction between helminths and 78 
bacteria. We show that helminths disrupt the metabolic profile of the small intestine, and that the 79 
resulting metabolites directly affect the virulence of S. Typhimurium to enhance bacterial 80 
colonization.  81 
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Methods: 82 
Mice 83 
All mouse experiments were performed at the University of British Columbia (UBC) and 84 
approved by UBC’s Animal Care Committee and the Canadian Council on Animal Care. 85 
Wildtype C57BL/6 mice were purchased from the Jackson Laboratory, and wildtype 86 
129S1/SvImJ, rag1-/-, C57BL/6 4get [21], C57BL/6 KN2/KN2 (il4-/-) [22] and C57BL/6 4get 87 
stat6-/- [23] mice were bred in-house. All mice were housed in individually ventilated cages in 88 
specific-pathogen-free conditions, with ad lib access to food and water. Experimental mice were 89 
age- and sex-matched and used at 6-12 weeks old. Littermates were randomized between test 90 
groups prior to the start of each experiment. 91 
Infections 92 
Mice were left naïve or infected by oral gavage with 200 H. polygyrus third stage larvae. Where 93 
indicated, naïve or day-14 H. polygyrus-infected mice were infected with streptomycin-resistant 94 
Salmonella enterica serovar Typhimurium wildtype or aroA mutant strain SL1344. 129S1/SvImJ 95 
mice were orally gavaged with 3 x 106 colony forming units (cfu) of stationary-phase S. 96 
Typhimurium in phosphate-buffered saline (PBS), from overnight cultures grown in LB broth. 97 
C57BL/6 mice were orally gavaged with 3 x 108 cfu of stationary-phase aroA mutant S. 98 
Typhimurium [24]. 99 
In vivo Salmonella burden quantification 100 
Serial dilutions of homogenized tissues were plated onto LB plates containing 100 µg/mL 101 
streptomycin (Sigma-Aldrich). The following day, S. Typhimurium colonies were counted and 102 
cfu per gram of tissue was calculated. 103 
Metabolite collection 104 
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Intestinal contents were collected from the proximal 6 cm of the small intestine of naïve or day-105 
14 H. polygyrus-infected mice, and weights were recorded. 100 µL of acetonitrile (VWR) was 106 
added for each 10 mg of intestinal content, and samples were shaken at 4 °C overnight. Samples 107 
were spun at 13,000 rpm at 4 °C for 15 minutes, and supernatants containing small molecules 108 
were collected. Supernatants were sterile-filtered, aliquoted into 250 µL (containing 25 mg 109 
intestinal contents) fractions, and acetonitrile was evaporated using a speed vacuum 110 
concentrator. Samples were stored at -80 °C prior to the use of metabolites for compositional 111 
analysis or functional assays. Control tubes were generated where acetonitrile was used as above 112 
to do mock extractions in an empty tube.  113 
Metabolite analysis 114 
In brief, metabolites were extracted as above from naïve or day-14 H. polygyrus-infected 115 
129S1/SvImJ mice and sent to the University of Victoria-Genome BC Proteomics Centre for 116 
untargeted metabolomics by Ultrahigh-Performance Liquid Chromatography-Fourier transform 117 
mass spectrometry (UPLC-FTMS) analysis. The positive ion and negative ion UPLC-FTMS 118 
datasets were processed individually, and the output of the data processing was the retention 119 
time, mass-to-charge ratio (m/z) and peak area of each detected metabolite or metabolite feature. 120 
Welch t-test with unequal variances was applied for the statistical analysis. Multivariate and 121 
clustering analyses were carried out using Metaboanalyst version 3.0 software 122 
(http://www.metaboanalyst.ca/faces/home.xhtml) [25,26], using a m/z tolerance of 0.0005 and a 123 
retention time tolerance of 30 seconds. Data were log transformed and auto scaled. Principal 124 
component analysis (PCA) was performed and plots were generated showing separation of data 125 
based on the first two principal components. Heat maps were generated showing relative 126 
abundance of all small intestinal metabolites. Maximum abundance was reported in red and 127 
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minimum abundance in blue. Clustering of samples from different mice was shown using a 128 
Euclidean distance and Ward clustering algorithm. Where possible, putative identities of 129 
identified metabolite features were assigned using the Metlin database 130 
(https://metlin.scripps.edu/metabo_batch.php) based on the m/z value of each feature. 131 
Statistical analyses were performed separately on datasets from positive and negative ion 132 
detection datasets. Full details are provided in the Supplementary Methods. 133 
Incubation of Salmonella with intestinal metabolites 134 
Mock extracted metabolites (control), metabolites from small intestinal contents of naïve mice, 135 
or metabolites from small intestinal contents of day-14 H. polygyrus-infected mice were 136 
resuspended in 1 mL of LB media and sterile-filtered using a 0.22 µΜ pore filter unit (Sigma-137 
Aldrich). 30 µL of stationary-phase overnight cultures of S. Typhimurium or aroA mutant S. 138 
Typhimurium grown in LB were diluted into the 1 mL of LB containing metabolites, and shaken 139 
at 37 °C for 3 hours. S. Typhimurium was then pelleted and resuspended in PBS twice, to wash 140 
cells.  141 
S. Typhimurium gene expression 142 
After incubation with metabolites as described above, S. Typhimurium was resuspended in 143 
RNAprotect Bacteria Reagent (Qiagen), and RNA was extracted using an RNeasy Mini Kit 144 
(Qiagen). Genomic DNA was removed using a DNA-Free™ kit (Ambion), and cDNA was 145 
prepared using a QuantiTect® Reverse Transcription Kit (Qiagen). Real-Time Quantitative PCR 146 
(qPCR) was performed on a 7500 Fast Real-Time PCR System (Applied Biosystems). Cycling 147 
conditions used were: 2 minutes at 50 °C, 15 minutes at 95 °C, followed by 40 cycles of 95 °C 148 
for 15 seconds, 58 °C for 30 seconds, 72 °C for 30 seconds. Primers used were (5’-3’) hilA: F-149 
ACACCTGCAGGATAATCCAA, R-ATTTTCGTGCCAGTTCATGT; sipA: F-150 
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GTCATAATGCCAGGTATGCAGACCG, R-CCTTTAATTTCCCCTGACAGCGTCG; sprB: 151 
F-CATTAACTGCACTTTTGCATTCCCTATCCG, R-152 
GCCACTACCAAAACTTTACGGTTCTGCA; and glyceraldehyde-3-phosphate dehydrogenase 153 
(gapA): F-GGCGCTAACTTTGACAAATACGAAGG, R-154 
AGTCATCAGACCTTCGATGATGCCG. Normalized expression units of test genes were 155 
calculated using the Delta-Delta Ct method relative to gapA. Expression levels were normalized 156 
to that of the control group (S. Typhimurium cultured with mock extracted metabolites) which 157 
was set to an expression level of 1. 158 
In vitro S. Typhimurium invasion assay 159 
HeLa cells were purchased from the American Type Culture Collection (ATCC) and cultured in 160 
DMEM (HyClone) containing 10 % heat-inactivated FBS (HyClone), 1 % GlutaMAX 161 
(ThermoFisher) and 1 % non-essential amino acids (Gibco) (complete DMEM), at 37 °C with 5 162 
% CO2. Cultures of S. Typhimurium that had been incubated with intestinal metabolites 163 
(described above) were used to infect HeLa cells at a multiplicity of infection of 50. S. 164 
Typhimurium inoculates were plated on LB plates containing 100 µg/mL streptomycin (Sigma-165 
Aldrich) to confirm the cfu of S. Typhimurium present in inoculates. Twenty minutes post-166 
infection HeLa cells were washed with PBS, and complete DMEM containing 50 µg/mL 167 
gentamicin (Gold Biotechnology) was added. After a further 70 minute incubation, HeLa cells 168 
were lysed using PBS containing 1 % Triton X-100 (Sigma-Aldrich) and 0.1 % sodium dodecyl 169 
sulfate (SDS; Sigma-Aldrich). Serial dilutions of lysate were plated onto LB plates containing 170 
100 µg/mL streptomycin (Sigma-Aldrich). The following day, S. Typhimurium colonies were 171 
counted and invasion level was calculated as the % of S. Typhimurium cfu present in inoculates 172 
that invaded HeLa cells. The control group (S. Typhimurium cultured with mock-extracted 173 
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metabolites) invasion level was set to 1, and invasion levels of other groups shown relative to 174 
this value. 175 
Statistical analysis 176 
Data were analysed for normality using a D’Agostino-Pearson omnibus normality test. For 177 
assessing differences between two groups, an unpaired t test was used for normally distributed 178 
data, and a Mann-Whitney test was used for data that were not normally distributed. When more 179 
than two test groups were being assessed, a one-way ANOVA followed by a Tukey’s multiple 180 
comparisons test was used for normally distributed data, and a Kruskal-Wallis test followed by a 181 
Dunn’s multiple comparisons test was used for data which were not normally distributed. A p 182 
value ≥ 0.05 was considered statistically significant. * = p £0.05, ** = p £ 0.01, *** = p £ 0.001, 183 
**** = p £ 0.0001, NS = not significant.  184 
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Results: 185 
Helminth co-infected mice exhibit elevated S. Typhimurium burdens in the small intestine 186 
To test the effects of intestinal helminth infection on bacterial co-colonization, we developed a 187 
model of co-infection using the murine helminth Heligmosomoides polygyrus and the bacteria S. 188 
Typhimurium. 129S1/SvImJ mice were orally infected with H. polygyrus, a strictly enteric 189 
pathogen which establishes a chronic infection in the small intestine [27]. At day fourteen 190 
following H. polygyrus infection, by which time adult worms are present in the lumen of the 191 
duodenum and jejunum, mice were orally challenged with S. Typhimurium, alongside mice 192 
infected with S. Typhimurium alone (Figure 1A). The majority of singly infected mice were able 193 
to clear S. Typhimurium from the small intestine within nine days, yet H. polygyrus co-infected 194 
mice maintained high bacterial burdens (Figure 1B). In the cecum and colon, sites distal to 195 
helminth infection, the effect of helminth co-infection on S. Typhimurium clearance was less 196 
marked, although helminth co-infection did result in significantly higher S. Typhimurium levels 197 
in the colon (Figure 1C). Levels of systemic S. Typhimurium were unaffected by helminth co-198 
infection (Figure 1D). Together, this data suggests that H. polygyrus exerts a local effect to 199 
promote S. Typhimurium colonization.  200 
To test if the effect of helminth infection on bacterial colonization was affected by genetic 201 
background, we also co-infected C57BL/6 mice (Figure 2A). Unlike 129S1/SvImJ mice, C57Bl/6 202 
mice lack the natural resistance-associated macrophage protein 1 (Nramp1), and rapidly succumb 203 
to infection with doses of wildtype S. Typhimurium that 129S1/SvImJ mice survive [28]. For this 204 
reason, all experiments with C57BL/6 mice were conducted with an attenuated strain of S. 205 
Typhimurium (aroA mutant [24]). Similar to 129S1/SvImJ mice, C57BL/6 mice infected with S. 206 
Typhimurium alone were able to clear this pathogen from the small intestine within nine days, 207 
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whereas helminth co-infected mice maintained high S. Typhimurium burdens in the small 208 
intestine (Figure 2B). The greatest impact of helminth co-infection was at sites proximal to H. 209 
polygyrus colonization (Figure 2C and D). Notably, small intestinal bacterial burdens were 210 
significantly higher in helminth co-infected mice as early as 24 hours following S. Typhimurium 211 
infection (Figure 2B). Therefore, in two different inbred strains of mice, the presence of an 212 
intestinal helminth enhances local bacterial colonization following challenge infection. 213 
Elevated S. Typhimurium burdens in helminth co-infected mice are independent of 214 
induction of Th2 or Treg cells 215 
Th2 cells induced by helminths have been previously shown to impair immunity to microbial 216 
infections [2–5]. We hypothesized, therefore, that the potent Th2 response induced by H. 217 
polygyrus [27] may be inhibiting effective bacterial clearance, leading to S. Typhimurium 218 
persistence. To test this, we co-infected mice that are unable to mount a Th2 response. 219 
Surprisingly, similar to co-infected wildtype mice, both il4-deficient, and stat6-deficient co-220 
infected mice failed to clear S. Typhimurium from the small intestine by day nine post-infection 221 
(Figure 3), suggesting that during co-infection increased susceptibility to secondary bacterial 222 
infection is independent of Th2 cells.  223 
In addition to induction of Th2 cells, H. polygyrus also stimulates expansion and activation of 224 
Tregs [29]. Therefore, Treg mediated immunosuppression of antibacterial responses could 225 
account for elevated bacteria burdens in co-infected mice. To test this, we co-infected rag1-226 
deficient mice, which lack all mature T cells including Tregs, as well as all mature B cells [30]. 227 
We compared S. Typhimurium burdens between singly-infected and helminth co-infected rag1-228 
deficient mice one day following S. Typhimurium infection, before differences in susceptibility 229 
to S. Typhimurium between wildtype and rag1-deficient mice emerge [31]. Similar to wildtype 230 
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mice, at one day following S. Typhimurium infection, helminth co-infected rag1-deficient mice 231 
had dramatically elevated S. Typhimurium burdens in the small intestine, compared to rag1-232 
deficient mice infected with S. Typhimurium alone (Figure 4). This suggests that during co-233 
infection suppression of immunity to S. Typhimurium is not mediated by helminth-induced 234 
Tregs. Together these data demonstrate that helminth infection can impair resistance to bacterial 235 
pathogens independently of Th2 or Treg conditioning of host immunity. 236 
Helminth infection alters the metabolic profile of the small intestine 237 
Colonization with helminth parasites has been associated with changes to the intestinal 238 
microbiota in both mice and humans [32]. H. polygyrus infection causes profound shifts in the 239 
composition of the small intestinal microbiota [33–35]. Alterations to the microbiota imposed by 240 
H. polygyrus have recently been demonstrated to enhance production of microbiota-derived short 241 
chain fatty acids, which can alleviate allergic airway inflammation [36]. Helminth infection has 242 
also been shown to inhibit the development of inflammatory bowel disease by reducing the 243 
prevalence of specific inflammatory species within the microbiota [37]. In both these cases, 244 
helminth-induced microbiota changes were seen to target host pathways. We hypothesized there 245 
may also be a direct effect of intestinal metabolic changes on concurrent microbial pathogens. 246 
We identified metabolites present in the small intestine by ultrahigh-performance liquid 247 
chromatography-Fourier transform mass spectrometry (UPLC-FTMS), and assessed the relative 248 
abundance of each metabolite between naïve and H. polygyrus-infected mice. Helminth infection 249 
significantly altered the metabolic profile of the small intestine (Figure 5A and B, Supplementary 250 
Figure 1A and B, Supplementary Figure 2A and B). Out of 4593 metabolite features detected, 362 251 
were significantly altered in abundance during H. polygyrus infection (p ≤0.01, ≥2-fold 252 
difference), with 41 upregulated and 321 suppressed during H. polygyrus infection (mass-to-253 
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charge ratio [m/z], retention time, and putative identities of metabolite features reported in 254 
Supplementary Figure 2A and B, Supplementary Tables 1 to 4). 255 
Helminth-modulated small intestinal metabolites promote S. Typhimurium 256 
intracellular invasion 257 
We next aimed to determine whether a helminth-altered metabolome had an impact on the 258 
growth or invasive capacity of S. Typhimurium. We first tested whether helminth-altered small 259 
intestinal metabolites affected the growth rate of S. Typhimurium, and found no evidence that 260 
helminth-altered small intestinal metabolites promoted the growth of S. Typhimurium in an in 261 
vitro growth assay (Supplementary Figure 3A and B).  We next investigated whether exposure to 262 
helminth-modulated small intestinal metabolites altered the expression levels of S. Typhimurium 263 
virulence genes. HilA is a bacterial transcription factor that plays a central role in regulating 264 
expression of S. Typhimurium genes controlling intracellular invasion, which are encoded within 265 
Salmonella pathogenicity island 1 (SPI-1) [38]. We found that hilA expression was inhibited in S. 266 
Typhimurium cultured with metabolites from naïve mice but not by metabolites from H. 267 
polygyrus-infected mice (Figure 6A). Expression levels of sipA and sprB, which are also found 268 
within the SPI-1 locus, were likewise elevated after culture with small intestinal metabolites 269 
from H. polygyrus-infected mice compared to after culture with small intestinal metabolites from 270 
naïve mice (Figure 6A). These data indicate that small intestinal metabolites altered in abundance 271 
during helminth infection promote the expression of virulence genes in S. Typhimurium. To 272 
determine whether the altered expression of S. Typhimurium virulence genes after exposure to 273 
helminth-modulated metabolites corresponded with an altered invasive capacity of S. 274 
Typhimurium, we tested the effect of metabolites from naïve or H. polygyrus-infected mice on S. 275 
Typhimurium intracellular invasion. Metabolites extracted from the small intestine of naïve 276 
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mice, either 129S1/SvImJ or C57BL/6, significantly suppressed the ability of S. Typhimurium to 277 
invade human epithelial (HeLa) cells (Figure 6B). In contrast, metabolites extracted from the 278 
small intestine of H. polygyrus-infected mice did not suppress the ability of S. Typhimurium to 279 
invade HeLa cells (Figure 6B). These data reveal for the first time that modulation of intestinal 280 
metabolites during helminth infection directly affects the invasive capacity of pathogenic S. 281 
Typhimurium bacteria. Together our data reveal a new interaction in helminth-bacterial co-282 
infection, in which helminth infection disrupts the protective composition of the intestinal 283 
metabolome, allowing for increased intracellular invasion and colonization by pathogenic 284 
bacteria.  285 
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Discussion: 286 
A number of studies have demonstrated that an ongoing helminth infection can result in 287 
heightened susceptibility to microbial pathogens. This was attributed to helminth mediated 288 
immunomodulation that acted to compromise the development of antimicrobial immune 289 
responses [1–5,13]. In this study, we describe a novel mechanism by which helminths increase 290 
susceptibility to a microbial pathogen, independently of immune conditioning toward Th2 or 291 
Treg responses. We provide evidence to show that the presence of helminths disrupts the 292 
metabolic composition of the intestine, and the resultant shift in metabolites directly alters the 293 
invasive capacity of the intracellular bacterial pathogen S. Typhimurium. 294 
Salmonella invasion gene expression is strongly repressed by metabolites extracted from the 295 
feces of naïve mice or humans [39]. These inhibitory metabolites are likely derived from both the 296 
microbiota as well as the mammalian host, as metabolites extracted from the feces of both germ-297 
free and conventionally-raised mice inhibited Salmonella invasion gene expression, although to a 298 
lesser extent by metabolites from germ-free mice [39]. Disruption of the intestinal metabolic 299 
environment by antibiotic treatment can promote S. Typhimurium expansion in mice [40]. 300 
Antibiotic treatment induces host expression of inducible nitric oxide synthase (iNOS), which 301 
mediates elevated carbohydrate oxidation, releasing galactarate and glucarate that can promote 302 
the expansion of S. Typhimurium [40]. H. polygyrus infection could disrupt the intestinal 303 
metabolome by shifting the composition of the microbiota, thereby altering the abundance 304 
microbiota-derived products [33–35], or by interfering with host metabolism. Additionally, it is 305 
possible that metabolites produced directly by helminths [36,41] are responsible for promoting 306 
Salmonella virulence. 307 
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It is becoming increasingly clear that complex communication between kingdoms occurs in the 308 
mammalian intestine. The bacterial microbiota and intestinal helminths share a niche within the 309 
host, and can influence each other’s fitness and persistence [32]. For example, the presence of 310 
the microbiota is critical for the establishment of Trichuris muris, a murine whipworm whose 311 
eggs hatch in the ceca [42]. For hatching, the eggs require direct contact with structural 312 
components of microbes within the intestinal microbiota [42]. Specific species within the 313 
microbiota can also affect the chronicity of adult helminths. Lactobacillus species promote the 314 
persistence of adult H. polygyrus and T. muris worms, likely through the induction of Tregs and 315 
inhibition of Th2 responses directed against the parasites [33,43]. A common pathway of inter-316 
bacterial communication in the intestine is through the production of bacterial-derived 317 
metabolites, which can shape the population dynamics of the bacterial microbiota, as well as 318 
influencing the ability of pathogenic bacteria to colonize the intestine [44]. Our work provides 319 
the first example of how helminths can influence the virulence of a pathogenic bacteria through 320 
an altered small intestinal metabolome. 321 
A helminth-altered cecal metabolome has been shown to mediate, at least in part, the suppression 322 
of airway inflammation during helminth infection in a murine model of allergic asthma [36]. It 323 
has been previously demonstrated that helminth infection results in elevated levels of short chain 324 
fatty acids (SCFAs) in the ceca of mice, which enhanced the suppressive function of Tregs and 325 
protected against airway inflammation [36]. Helminths may have evolved the ability to shift the 326 
metabolite profile towards one which promotes their own chronicity, for example, through 327 
inducing SCFA which have been shown to induce and enhance the suppressive function of Tregs 328 
[45–47]. There is a current interest in the use of helminths, or helminth-derived products, for the 329 
therapeutic treatment of inflammatory diseases including allergy and inflammatory bowel 330 
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disease [48]. As our data and others suggests that helminth infection can also increase 331 
susceptibility to microbial infections [2–6], it will be important to fully characterize the pathways 332 
by which helminths affect host physiology, such that susceptibility to pathogenic microbes 333 
during therapeutic administration of helminths can be predicted and controlled.  334 
Helminths are potent immunomodulators, which can alter host immunity to infectious and 335 
immune-mediated diseases through multiple mechanisms, dependent on the disease context, host 336 
genetics, and the microbiota [13,36,37]. Both helminths and the microbiota have potent 337 
immunomodulatory effects during inflammatory and infectious diseases [13,32,49,50]. Our data 338 
identify a novel mechanism by which a helminth-modified metabolic environment can promote 339 
the ability of a bacterial pathogen to colonize the intestine. Understanding the mechanisms by 340 
which helminths promote susceptibility to microbial co-infections will aid disease treatment and 341 
prevention strategies in the world regions where helminths are prevalent. 342 
Word count: 3500 343 
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Figure Legends: 497 
 498 
Figure 1. Helminth co-infected 129S1/SvlmJ mice exhibit elevated S. Typhimurium 499 
burdens in the small intestine. A, Experimental set up. 129S1/SvImJ mice were left naïve or 500 
infected with H. polygyrus (Hp). Fourteen days later, all mice were orally infected with S. 501 
Typhimurium (ST). Nine days later, S. Typhimurium cfu counts were determined. B, S. 502 
Typhimurium cfu counts in the duodenum and jejunum. C, S. Typhimurium cfu counts in the 503 
cecum and colon. D, S. Typhimurium cfu counts in the spleen and liver. Data shown are pooled 504 
from two independent experiments and are representative of the results from three independent 505 
experiments. 506 
 507 
Figure 2. Helminth co-infected C57BL/6 mice exhibit elevated S. Typhimurium burdens in 508 
the small intestine. A, Experimental set up. C57BL/6 mice were left naïve or infected with H. 509 
polygyrus (Hp). Fourteen days later, all mice were orally infected with aroA mutant S. 510 
Typhimurium (ST). One and nine day(s) later, S. Typhimurium cfu counts were determined. B, S. 511 
Typhimurium cfu counts in the duodenum and jejunum. C, S. Typhimurium cfu counts in the 512 
cecum and colon. D, S. Typhimurium cfu counts in the spleen and liver. Data shown are pooled 513 
from two independent experiments and are representative of the results from four independent 514 
experiments. 515 
 516 
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Figure 3. Elevated S. Typhimurium burdens in helminth co-infected mice are independent 517 
of induction of Th2 cells. 518 
C57BL/6, il4-/- and stat6-/- mice were left naïve or infected with H. polygyrus. Fourteen days 519 
later, all mice were orally infected with aroA mutant S. Typhimurium. Nine days later, S. 520 
Typhimurium cfu counts were determined in the duodenum and jejunum. Data shown are pooled 521 
from two independent experiments. 522 
 523 
Figure 4. Elevated S. Typhimurium burdens in helminth co-infected mice are independent 524 
of induction of Treg cells. 525 
C57BL/6 and rag1-/- mice were left naïve or infected with H. polygyrus. Fourteen days later, all 526 
mice were orally infected with aroA mutant S. Typhimurium. One day later, S. Typhimurium cfu 527 
counts were determined in the duodenum and jejunum. Data shown are pooled from three 528 
independent experiments. 529 
 530 
Figure 5. Helminth infection alters the metabolic profile of the small intestine. 531 
A, The differential abundance of small intestinal metabolites from naïve or day-14 H. polygyrus-532 
infected (Hp) 129S1/SvImJ mice was determined by UPLC-FTMS. A principal component 533 
analysis (PCA) plot was generated from metabolites detected in positive ion mode. B, A heat 534 
map showing the relative abundance of all metabolites detected in naïve and day-14 H. 535 
polygyrus–infected mice 129S1/SvImJ mice, detected in positive ion mode. Clustering of naïve 536 
and H. polygyrus-infected mice is shown using a Euclidean distance and Ward clustering 537 
algorithm. 538 
 539 
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Figure 6. Helminth-modified small intestinal metabolites promote intracellular invasion by 540 
S. Typhimurium. A, aroA mutant S. Typhimurium bacteria were cultured without metabolites 541 
(control) or with metabolites extracted from the small intestine of naïve or H. polygyrus-infected 542 
C57BL/6 mice. Expression levels of S. Typhimurium hilA, sipA and sprB were then determined. 543 
Each data point represents gene expression levels of three S. Typhimurium cultures that were 544 
split and cultured with metabolites from each group. Data shown are representative of results 545 
from four independent experiments that each used independent mice and S. Typhimurium 546 
cultures. B, Wildtype or aroA mutant S. Typhimurium bacteria were cultured without 547 
metabolites (control) or with metabolites extracted from the small intestine of naïve or H. 548 
polygyrus-infected 129S1/SvImJ or C57BL/6 mice, prior to infection of HeLa cells. Each data 549 
point represents a technical replicate of HeLa cells infected with S. Typhimurium that had been 550 
cultured with metabolites pooled from 3-5 naïve or 3 H. polygyrus-infected mice. Data are 551 
representative of results from two (129S1/SvImJ) or three (C57BL/6) independent experiments 552 
that each used independent mice and S. Typhimurium cultures.  553 
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Supplementary Methods 1 
Metabolite analysis 2 
Three samples containing metabolite extracts from 25 mg of small intestinal contents from naïve 3 
129S1/SvImJ mice and 3 samples containing extracts from 25 mg of day 14 H. polygyrus-4 
infected 129S1/SvImJ mice were obtained as described above. Each sample contained pooled 5 
small intestinal content from 2-3 naïve or H. polygyrus-infected mice. Samples were sent to the 6 
University of Victoria-Genome BC Proteomics Centre for untargeted metabolomics by 7 
Ultrahigh-Performance Liquid Chromatography-Fourier transform mass spectrometry (UPLC-8 
FTMS) analysis. Each of the dried residues of intestinal contents was dissolved in 200 µL of 75 9 
% aqueous methanol. After vortex mixing, sonication for 1 minute in an ice water bath, and 10 
centrifugation at 15,000 rpm and 5 °C in an Eppendorf 5420 R centrifuge for 10 minutes, 5 µL of 11 
the supernatants were injected for UPLC-FTMS into a C8 column (2.1 x 50 mm, 1.7 µm). The 12 
UPLC-MS instrument was a Waters Acquity UPLC system coupled to a Thermo Scientific LTQ-13 
Orbitrap Fusion mass spectrometer. The MS instrument was operated in the survey scan mode 14 
with Fourier transform (FT) MS detection at a resolution of 120,000 FWHM (m/z 400) for 15 
metabolite detection and relative quantitation. For assistance of metabolite identification, LC-16 
MS/MS data using collision induced dissociation were acquired. The metabolites were detected 17 
within m/z 80 to 1200 and in positive and negative ion detection modes, respectively. Two LC-18 
MS runs per sample were performed. The mobile phase was 0.01 % formic acid in water (A) and 19 
acetonitrile-isopropanol (1:1, v/v) containing 0.01 % formic acid (B) for binary solvent gradient 20 
elution. The gradient was 5% to 40 % B in 5 minutes; 40 % to 100 % B in 15 minutes; 100 % B 21 
for 2 minutes and then the column was reconditioned at 5 % B for 4 minutes between injections. 22 
The flow rate was 0.35 mL/minute and the column temperature was 45 °C. 23 
 2 
The positive ion and negative ion UPLC-FTMS datasets were respectively processed using the 24 
XCMS (https://xcmsonline.scripps.edu/) suite in R for peak detection, retention time shift 25 
correction, peak grouping and peak alignment [1]. Mass de-isotoping was performed manually. 26 
The output of the data processing was the retention time, mass to charge ratio (m/z) and peak 27 
area of each detected metabolite or metabolite feature from each LC-MS dataset. Welch t-test 28 
with unequal variances was applied for the statistical analysis. Multivariate and clustering 29 
analyses were carried out using Metaboanalyst version 3.0 software 30 
(http://www.metaboanalyst.ca/faces/home.xhtml) [2,3], using a m/z tolerance of 0.0005 and a 31 
retention time tolerance of 30 seconds. Data were log transformed and autoscaled. Principal 32 
component analysis (PCA) was performed and plots were generated showing separation of data 33 
based on the first two principal components. Heat maps were generated showing the relative 34 
abundance of all small intestinal metabolites. Maximum abundance was reported in red and 35 
minimum abundance was reported in blue. Clustering of samples from different mice was shown 36 
using a Euclidean distance and Ward clustering algorithm. Where possible, putative identities of 37 
identified metabolite features were assigned using the online Metlin database 38 
(https://metlin.scripps.edu/metabo_batch.php) based on the m/z value of each metabolite feature. 39 
Statistical analyses were performed separately on datasets from positive and negative ion 40 
detection datasets.  41 
In vitro S. Typhimurium growth assay 42 
Metabolites extracted from small intestinal contents of naïve C57BL/6 or 129S1/SvImJ mice, or 43 
metabolites extracted from small intestinal contents of day 14 H. polygyrus-infected C57BL/6 or 44 
129S1/SvImJ mice were resuspended in LB media, and sterile-filtered through a 0.22 µΜ pore 45 
filter unit (Sigma-Aldrich). 150 µl of LB media containing metabolites extracted from 3.75 mg 46 
 3 
of small intestinal contents was added to each well of a 96-well transparent flat bottom plate. 4 µl 47 
of stationary-phase overnight cultures of S. Typhimurium or aroA mutant S. Typhimurium (as 48 
indicated) grown in LB were diluted into LB containing metabolites from naïve or H. polygyrus-49 
infected mice, and were shaken at 37 °C for 16 hours in an Infinite® 200 PRO plate reader 50 
(Tecan). Absorbance of cultures was measured at 600 nm over 16 hours. Each curve plotted 51 
tracks the growth of a S. Typhimurium culture with metabolites extracted from an individual 52 
mouse, and error bars denote the standard error of three technical replicates. 53 
  54 
 4 
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 65 
Supplementary Figure 1. Helminth infection alters the metabolite profile of the small 66 
intestine. A, Untargeted UPLC-FTMS was performed to determine the differential abundance of 67 
metabolites in the small intestine of naïve or day 14 H. polygyrus-infected (Hp) 129S1/SvImJ 68 
mice. A principal component analysis (PCA) plot was generated from metabolites detected in the 69 
negative ion mode. B, A heat map showing the relative abundance of all small intestinal 70 
metabolites detected in naïve and day 14 H. polygyrus–infected mice 129S1/SvImJ mice, 71 
detected by in the negative ion mode. Clustering of naïve and day 14 H. polygyrus-infected mice 72 
is shown using a Euclidean distance and Ward clustering algorithm.   73 
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 74 
Supplementary Figure 2. Helminth infection alters the metabolite profile of the small 75 
intestine. Untargeted UPLC-FTMS was performed to identify the differential abundance of 76 
metabolites in the small intestine of naïve or day 14 H. polygyrus-infected (Hp) 129S1/SvImJ 77 
mice. The relative abundance of all metabolite features, described by mass to charge ratio (m/z) 78 
and retention time (rt) (shown on labels as m/z/rt) is shown. All metabolite features significantly 79 
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altered (p <0.01), with greater than a 100-fold difference in abundance between naïve and H. 80 
polygyrus-infected mice are shown. A, Detected in positive ion mode. B, Detected in negative 81 
ion mode.  82 
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 83 
Supplementary Figure 3. Metabolites extracted from the small intestine of Hp-infected 84 
mice do not increase the growth rate of S. Typhimurium. Metabolites were extracted from the 85 
small intestine of naïve or day-14 H. polygyrus (Hp) infected 129S1/SvImJ (A) or C57BL/6 (B) 86 
mice and cultured with wildtype (A) or aroA mutant (B) S. Typhimurium bacteria in LB 87 
medium. S. Typhimurium growth was tracked over 16 hours by measuring optical density at 600 88 
nm. Each curve tracks the growth of a S. Typhimurium culture with metabolites extracted from 89 
an individual mouse, and error bars denote the standard error of three technical replicates.  90 
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Supplementary Table 1. Putative identities of metabolites detected in positive ion mode 91 
upregulated in the small intestine of uninfected mice compared with H. polygyrus-infected 92 
mice. 93 
Untargeted UPLC-FTMS was performed to identify the differential abundance of metabolites in 94 
the small intestine of naïve or day 14 H. polygyrus-infected 129S1/SvImJ mice. Those 95 
metabolites significantly upregulated (p= <0.01) in the small intestine of naïve, compared to H. 96 
polygyrus-infected mice, that were detected in positive ion mode, are reported. m/z= mass to 97 
charge ratio, rt= column retention time, fold= fold change. Putative identities (IDs) were 98 
assigned to each metabolite feature where possible. 99 
 100 
m/z rt fold Putative ID (s) Formula Class 
811.4821 10.2 Inf Unknown - - 
1016.66462 10.93 Inf Multiple C50H98NO17P Phosphosphingolipids 
1051.1608 10.17 2919.9 Unknown - - 
799.48246 10.17 849.5 Unknown - - 
791.49292 10.17 770.9 Unknown - - 
833.47629 10.17 622.9 Unknown - - 
991.67426 10.93 476.3 Unknown - - 
755.49348 10.93 372.6 Chikusetsusaponin Ia C41H70O12 Steroidal Glycosides  
763.48257 10.93 274.1 Unknown - - 
814.49163 10.2 232.4 Unknown - - 
766.49126 10.93 210.0 Unknown - - 
803.49521 10.18 175.6 SQDG(16:0/14:0) C40H76O12S Glycosyldiacylglycerols 
754.9915 10.93 148.1 Unknown - - 
539.31371 10.17 74.8 Unknown - - 
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531.32451 10.17 66.1 Unknown - - 
551.31325 10.21 63.1 
Neolinderatone or 
Neolinderachalcone C35H44O4 Flavonoids 
583.29975 10.24 60.6 
PG(22:4(7Z,10Z,13Z,16Z)
/0:0) C28H49O9P Glycerophosphoglycerols 
515.31371 10.93 53.2 Unknown - - 
524.30058 10.93 51.1 Unknown - - 
547.29899 10.17 35.9 Unknown - - 
838.49118 10.23 34.7 Unknown - - 
813.03732 17.02 25.7 Unknown - - 
444.27975 11.02 24.9 Unknown - - 
573.30695 10.17 22.5 Unknown - - 
520.34001 10.17 21.8 Multiple C26H50NO7P Glycerophosphocholines 
724.43964 12.31 21.5 Unknown - - 
541.40748 12.43 20.9 Unknown - - 
783.57384 17.1 20.9 Unknown - - 
523.34809 10.17 20.0 Unknown - - 
544.34016 10.23 20.0 Multiple C28H50NO7P Glycerophosphocholines 
566.32209 10.24 19.4 Multiple C28H50NO7P Glycerophosphocholines 
539.39103 12.9 19.2 Unknown - - 
782.57052 17.09 18.4 Multiple C44H80NO8P 
Glycerophosphoethanolamine
s or Glycerophospholipids  
497.34335 10.93 18.2 Unknown - - 
626.27713 9.47 18.2 Unknown - - 
803.03827 16.99 17.8 Unknown - - 
540.31739 10.18 17.6 Unknown - - 
542.32226 10.17 17.5 Multiple C26H50NO7P Glycerophosphocholines 
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524.3623 11.31 17.3 Unknown - - 
496.34 10.93 17.2 Multiple C24H50NO7P Glycerophosphocholines 
534.29657 10.93 16.4 Unknown - - 
568.34019 10.38 16.4 Multiple C30H50NO7P Glycerophosphocholines 
590.32244 10.38 16.1 Multiple C30H50NO7P Glycerophosphocholines 
518.32185 10.93 15.6 Multiple C24H50NO7P Glycerophosphocholines 
764.53568 11.88 14.6 Unknown - - 
548.3628 10.72 14.6 Unknown - - 
568.33818 10.72 13.9 Unknown - - 
546.34397 11.31 13.7 Unknown - - 
830.49992 10.64 13.5 Unknown - - 
526.30455 10.93 13.5 Unknown - - 
544.33787 11.31 13.2 Multiple C26H52NO7P Glycerophosphocholines 
658.33594 10.15 13.1 Unknown - - 
521.32983 10.94 13.1 Unknown - - 
852.55241 16.88 12.5 Multiple C50H78NO8P Glycerophospholipids 
291.16958 12.31 12.4 Unknown - - 
804.55492 16.57 12.4 Multiple C46H78NO8P Glycerophosphocholines  
367.27659 12.41 12.2 Unknown - - 
522.35585 11.31 12.0 Multiple C26H52NO7P Glycerophosphocholines 
419.27163 10.96 11.7 Unknown - - 
422.25571 16.58 11.7 Unknown - - 
569.34148 10.71 11.6 Unknown - - 
968.56647 16.66 11.5 Unknown - - 
240.09959 10.18 11.5 Unknown - - 
361.27391 11.89 11.4 Multiple C23H36O3 Secosteroids 
682.04008 12.45 11.3 Unknown - - 
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852.48157 10.64 11.0 Unknown - - 
588.40043 11.88 11.0 Multiple C29H60NO7P Glycerophosphocholines 
289.17698 10.93 10.9 Multiple C16H26O3 Fatty Acids and Conjugates 
826.53694 16.58 10.9 Multiple C48H76NO8P Glycerophosphocholines 
508.33982 10.65 10.8 Multiple C25H50NO7P 
Glycerophosphocholines or 
Glycerophospholipids  
292.14866 10.24 10.8 Unknown - - 
887.56514 12.3 10.7 Multiple C47H83O13P 
Glycosylglycerophospho-
lipids 
550.30507 10.42 10.6 Unknown - - 
558.29634 10.43 10.5 Unknown - - 
363.28926 12.39 10.4 Multiple C23H38O3 Bile Acids and Derivatives 
587.39702 11.88 10.4 Unknown - - 
680.31787 10.14 10.4 Unknown - - 
293.15681 10.72 10.2 Unknown - - 
886.56173 12.31 10.2 Unknown - - 
548.37157 11.67 10.2 Multiple C28H55NO7P Glycerophosphocholines 
559.29999 10.44 10.2 PG(20:2(11Z,14Z)/0:0) C26H49O9P Glycerophosphoglycerols 
478.33004 10.93 10.2 
PC(O-
16:2(9E,10E)/0:0)[U] C24H48NO6P 
Glycerophosphoethanol-
amines or 
Glycerophosphocholines  
284.15957 10.24 10.2 Unknown - - 
606.30837 11.31 10.1 Unknown - - 
411.2828 10.96 10.1 Unknown - - 
508.28291 10.48 10.0 Unknown - - 
818.51064 16.99 9.9 Unknown - - 
832.57727 16.87 9.8 Unknown - - 
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277.15406 10.93 9.8 Unknown - - 
496.3399 10.65 9.7 Multiple C24H50NO7P Glycerophosphocholines 
908.54341 12.31 9.6 Unknown - - 
830.57087 16.87 9.5 Multiple C48H80NO8P Glycerophosphocholines 
846.4638 10.64 9.5 Unknown - - 
814.04534 17.08 9.5 Unknown - - 
280.14858 10.17 9.3 Unknown - - 
281.15647 11.31 8.9 Unknown - - 
798.09469 18.17 8.9 Unknown - - 
288.1602 10.93 8.6 Unknown - - 
272.15969 10.17 8.5 Unknown - - 
296.14662 10.93 8.3 Unknown - - 
435.26343 16.88 8.2 Unknown - - 
272.6661 11.32 8.1 Unknown - - 
548.275 10.48 8.0 Multiple C27H44NO7P 
Glycerophosphoethanol-
amines 
293.6626 11.67 8.0 Unknown - - 
630.30896 10.72 7.9 Unknown - - 
541.31019 10.17 7.8 Unknown - - 
473.19758 10.52 7.8 Unknown - - 
808.58634 17.67 7.7 Multiple C46H82NO8P 
Glycerophosphoethanol-
amines or 
Glycerophosphocholines  
549.27846 10.48 7.6 Unknown - - 
268.1486 10.93 7.5 Unknown - - 
303.19222 12.31 7.4 Unknown - - 
920.56633 16.91 7.3 Unknown - - 
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258.6235 10.52 7.3 Unknown - - 
459.24881 10.93 7.3 Multiple C21H41O7P 
Glycerophosphates or 
Carbonyl Compounds  
409.21932 6.51 6.9 Oleandolide C20H34O7 
Macrolides and Lactone 
Polyketides 
834.50511 16.94 6.9 Multiple C47H74NO8P 
Glycerophosphoethanol-
amines 
780.55506 17 6.8 Multiple C44H78NO8P 
Glycerophosphoethanol-
amines or 
Glycerophosphocholines  
437.27913 17.93 6.8 Unknown - - 
816.54329 12.35 6.8 Unknown - - 
792.04419 16.99 6.7 Unknown - - 
802.53687 17 6.6 Multiple C46H76NO8P 
Glycerophosphocholines or 
Glycerophosphoethanol-
amines 
806.57039 17.06 6.6 Multiple C46H80NO8P 
Glycerophosphocholines or 
Glycerophosphoethanol-
amines 
858.58972 17.93 6.6 
LacCer(d18:0/14:0) or 
LacCer(d14:0/18:0) C44H85NO13 Neutral Glycosphingolipids 
822.5658 16.05 6.5 Multiple C46H80NO9P Glycerophosphoserines 
282.16423 12.31 6.5 Unknown - - 
808.57679 17.06 6.4 Unknown - - 
804.54275 16.99 6.4 Unknown - - 
280.14876 10.42 6.4 Unknown - - 
500.31375 16.6 6.3 Unknown - - 
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535.30002 10.94 6.1 
PG(18:0/0:0)[U] or 
PG(18:0/0:0) C24H49O9P Glycerophosphoglycerols  
628.29241 10.23 6.1 Unknown - - 
902.52579 12.31 6.0 Unknown - - 
681.037 12.45 6.0 Unknown - - 
784.57692 17.11 6.0 Unknown - - 
447.30305 12.39 5.9 Unknown - - 
794.57125 17.32 5.8 Unknown - - 
345.2103 10.72 5.7 Unknown - - 
571.38293 12.01 5.7 Unknown - - 
586.31032 10.92 5.7 Unknown - - 
360.22077 10.17 5.5 Unknown - - 
802.53704 16.61 5.5 Multiple C44H78NO8P 
Glycerophosphocholines or 
Glycerophosphoethanol-
amines 
609.3273 12.3 5.3 Unknown - - 
856.58386 17.93 5.2 Multiple C50H82NO8P 
Glycerophosphocholines or 
Glycerophosphoethanol-
amines 
608.32438 12.31 5.2 Unknown - - 
580.29259 10.93 5.1 Unknown - - 
797.6452 19.98 4.9 Unknown - - 
870.52458 16.99 4.8 Multiple C47H78NO10P Glycerophosphoserines 
341.17874 9.47 4.8 Unknown - - 
385.27376 11.76 4.7 Unknown - - 
810.09233 18.13 4.7 Unknown - - 
604.2927 10.17 4.7 Unknown - - 
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328.28456 12.38 4.6 N-palmitoyl alanine C19H37NO3 Fatty Amides 
652.29294 10.37 4.5 Unknown - - 
605.29616 10.17 4.4 Multiple C32H44O11 Bufanolides and Derivatives 
399.26558 12.15 4.4 
10'-Apo-beta-caroten-10'-
al or 10'-apo-beta-
carotenal C27H36O Sesterterpenoids  
269.22641 12 4.4 Unknown - - 
478.3293 17 4.4 
PC(O-
16:2(9E,10E)/0:0)[U] or 
PE(P-19:1(12Z)/0:0) C24H48NO6P 
Glycerophosphocholines or 
Glycerophosphoethanol-
amines 
766.53681 18.33 4.3 Multiple C43H76NO8P 
Glycerophosphocholines or 
Glycerophosphoethanol-
amines 
502.32946 17.1 4.3 Unknown - - 
758.57081 17.52 4.2 Multiple C42H80NO8P 
Glycerophosphocholines or 
Glycerophosphoethanol-
amines 
564.3998 12.01 4.1 Unknown - - 
410.25564 17 4.1 Unknown - - 
504.32991 12.85 4.1 Unknown - - 
313.27369 12.45 4.1 Multiple C19H36O3 Fatty Acids and Conjugates 
517.30966 10.93 4.1 Unknown - - 
341.17862 17 4.0 Unknown - - 
852.55505 16.34 3.9 Multiple C50H78NO8P Glycerophosphocholines 
817.51574 11.88 3.9 Unknown - - 
503.33294 17.11 3.9 Unknown - - 
745.51501 12.46 3.8 Unknown - - 
 17 
770.06236 17.52 3.8 Unknown - - 
752.53568 11.88 3.8 Unknown - - 
753.03777 11.88 3.8 Unknown - - 
430.40426 8.99 3.7 Unknown - - 
487.2371 11.76 3.6 Unknown - - 
428.38861 8.95 3.6 Unknown - - 
411.26348 17.12 3.4 Unknown - - 
555.22439 11.76 3.4 Unknown - - 
213.13076 11.76 3.2 Unknown - - 
749.54868 19.63 3.2 Ubiquinone 8 C49H74O4 Quinones and Hydroquinones 
341.30494 13.77 3.1 Multiple C21H40O3 Fatty Acids and Conjugates 
339.28049 11.88 3.1 Unknown - - 
406.30313 12.15 3.0 Unknown - - 
477.43033 16.1 3.0 Unknown - - 
471.25925 11.76 2.9 Unknown - - 
795.63005 20.25 2.9 Coenzyme Q9 C54H82O4 Quinones and Hydroquinones 
533.34111 11.63 2.9 Unknown - - 
339.28947 12.81 2.8 Glycidyl oleate C21H38O3 - 
401.22116 11.71 2.8 Unknown - - 
337.2739 11.88 2.8 Multiple C21H36O3 Fatty Acids and Conjugates  
705.58037 19.8 2.8 Multiple C40H81O7P Glycerophosphates 
311.25805 11.41 2.8 Multiple C19H34O3 Fatty Acids and Conjugates 
655.56701 19.36 2.7 
5-Hydroxy-7-methoxy-2-
tritriacontyl-4H-1-
benzopyran-4-one C43H74O4 Benzopyrans 
819.61858 20.24 2.7 Unknown - - 
579.4285 12.95 2.6 Unknown - - 
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953.73405 12.44 2.6 Unknown - - 
812.65651 20.25 2.6 Unknown - - 
390.26917 11.88 2.6 Unknown - - 
367.3358 15.53 2.6 Unknown - - 
396.31055 12 2.5 Unknown - - 
575.39681 11.88 2.5 Unknown - - 
1056.7855 12.8 2.4 Unknown - - 
461.22143 11.09 2.4 Unknown - - 
404.28774 11.84 2.4 Unknown - - 
354.27212 11.05 2.3 Unknown - - 
335.25819 11.05 2.2 Unknown - - 
101 
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Supplementary Table 2. Putative identities of metabolites detected in negative ion mode 102 
upregulated in the small intestine of uninfected mice compared with H. polygyrus-infected 103 
mice. 104 
Untargeted UPLC-FTMS was performed to identify the differential abundance of metabolites in 105 
the small intestine of naïve or day 14 H. polygyrus-infected 129S1/SvImJ mice. Those 106 
metabolites significantly upregulated (p= <0.01) in the small intestine of naïve, compared to H. 107 
polygyrus-infected mice, that were detected in negative ion mode, are reported. m/z= mass to 108 
charge ratio, rt= column retention time, fold= fold change. Putative identities (IDs) were 109 
assigned to each metabolite feature where possible. 110 
 111 
m/z rt fold Putative ID (s) Formula Class 
1085.67681 10.17 125.7 Unknown - - 
654.30631 9.47 28.2 Unknown - - 
868.6123 18.41 20.9 Unknown - - 
594.38126 12.54 17.9 Unknown - - 
246.09946 0.4 17.8 Unknown - - 
590.33982 10.25 16.9 Unknown - - 
816.58142 17.83 16.3 Unknown - - 
590.34974 10.72 16.2 Unknown - - 
862.56932 12.31 16.1 Unknown - - 
806.50684 10.65 16.0 Unknown - - 
553.31668 10.38 15.9 Unknown - - 
848.5496 16.57 15.8 Unknown - - 
614.34006 10.38 15.5 Unknown - - 
504.31245 10.18 13.7 Unknown - - 
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564.33384 10.18 13.2 Unknown - - 
567.34149 10.17 13.2 Unknown - - 
658.33804 10.72 13.1 Unknown - - 
588.334 10.24 12.9 Unknown - - 
916.53792 16.57 12.7 Unknown - - 
540.33378 10.93 12.3 Unknown - - 
480.31206 10.93 12.0 Unknown - - 
524.33853 10.42 11.4 Unknown - - 
506.32777 11.31 11.3 Unknown - - 
602.3056 10.38 11.3 Unknown - - 
566.34943 11.31 11.0 Unknown - - 
606.514 17.56 10.9 Unknown - - 
528.31241 10.26 10.9 Unknown - - 
874.56549 16.87 10.9 Unknown - - 
633.51379 12.39 10.7 Unknown - - 
508.34348 12.31 10.7 Unknown - - 
634.33739 11.31 10.6 Unknown - - 
702.32565 11.31 10.3 Unknown - - 
354.30285 13.32 10.3 Unknown - - 
556.32084 11.31 10.2 Unknown - - 
506.3184 10.17 10.2 Unknown - - 
748.30992 10.37 10.2 Unknown - - 
568.36515 12.31 10.0 Unknown - - 
942.55342 16.87 10.0 Unknown - - 
578.30525 10.24 10.0 Unknown - - 
529.31567 10.24 10.0 Unknown - - 
704.24481 10.35 9.9 Unknown - - 
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592.36535 11.67 9.4 Unknown - - 
424.2806 11.88 9.1 Unknown - - 
558.33673 12.31 9.0 Unknown - - 
612.26415 10.93 8.9 Unknown - - 
840.58067 17.79 8.7 Unknown - - 
930.55787 12.3 8.6 Unknown - - 
530.30541 10.93 8.5 Unknown - - 
554.30573 10.18 8.5 Unknown - - 
796.55503 11.3 8.3 Unknown - - 
558.23993 10.35 8.1 Unknown - - 
423.27725 11.89 8.1 Unknown - - 
838.56582 17.34 8.0 Unknown - - 
636.35302 12.31 8.0 Unknown - - 
592.26879 10.28 8.0 Unknown - - 
598.21808 5.97 7.6 Unknown - - 
593.27228 10.29 7.6 Multiple C27H47O12P Glycerophosphoinositols 
844.57426 12.36 7.6 Unknown - - 
632.32251 10.2 7.6 Unknown - - 
698.3243 12.3 7.6 Unknown - - 
422.29093 13.32 7.4 Unknown - - 
884.56866 17.83 7.1 Unknown - - 
718.29317 10.24 7.1 Unknown - - 
856.61173 18.33 7.1 Unknown - - 
918.55598 16.9 6.8 Unknown - - 
608.32172 10.93 6.7 Unknown - - 
568.49778 17.6 6.6 Unknown - - 
679.49896 11.98 6.5 Unknown - - 
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827.55857 16.98 6.4 Multiple C43H85O10P Glycerophosphoglycerols 
613.25991 10.52 6.4 Unknown - - 
660.25691 10.29 6.3 Unknown - - 
670.29283 10.93 6.3 Unknown - - 
704.34118 12.3 6.2 Unknown - - 
554.30504 10.44 6.2 Unknown - - 
885.49483 17.92 5.9 Unknown - - 
592.26868 10.48 5.6 Unknown - - 
824.55024 16.99 5.4 Unknown - - 
878.5967 17.92 5.4 Unknown - - 
743.54739 18.32 5.4 Unknown - - 
326.27159 12.37 5.1 Unknown - - 
742.54401 18.33 4.9 Unknown - - 
810.53187 18.32 4.7 Unknown - - 
946.58455 17.93 4.5 Unknown - - 
494.32784 11.62 4.2 Unknown - - 
449.28353 11.76 4.0 Multiple C27H42O3 Secosteroids 
475.41797 16.09 3.7 Unknown - - 
598.29275 10.94 3.7 Unknown - - 
830.59721 18.17 3.7 Unknown - - 
447.27744 11.76 3.6 Unknown - - 
700.31002 10.19 3.5 Unknown - - 
415.24549 12 3.5 Unknown - - 
449.29306 12.16 3.4 Unknown - - 
659.53034 12.79 3.1 Unknown - - 
375.2769 12.45 3.0 Unknown - - 
439.24602 11.76 3.0 Unknown - - 
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403.30825 13.79 3.0 Unknown - - 
373.26118 11.41 3.0 Unknown - - 
606.23977 10.3 2.9 Unknown - - 
128.03545 0.42 2.9 Multiple C5H7NO3 
Carboxylic Acids and 
Derivatives 
402.29596 12.83 2.9 Unknown - - 
366.2515 12.44 2.9 Unknown - - 
639.56118 13.78 2.8 Unknown - - 
414.25168 11.96 2.8 Unknown - - 
583.49769 12.43 2.8 Unknown - - 
534.23955 10.3 2.8 Multiple C25H42NO7P 
Glycerophosphoethanol-
amines  
655.49867 12.01 2.7 Unknown - - 
503.27103 7.77 2.7 Unknown - - 
384.22321 10.01 2.6 Unknown - - 
365.2689 15.3 2.5 Unknown - - 
401.29261 12.89 2.5 Unknown - - 
347.24546 10.97 2.4 Unknown - - 
401.28266 11.88 2.1 Unknown - - 
361.26132 11.72 2.1 Unknown - - 
399.27703 11.89 2.1 Unknown - - 
348.24885 10.98 2.0 Unknown - - 
 112 
 113 
  114 
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Supplementary Table 3. Putative identities of metabolites detected in positive ion mode 115 
upregulated in the small intestine of H. polygyrus-infected compared with uninfected mice. 116 
Untargeted UPLC-FTMS was performed to identify the differential abundance of metabolites in 117 
the small intestine of naïve or day 14 H. polygyrus-infected 129S1/SvImJ mice. Those 118 
metabolites significantly upregulated (p= <0.01) in the small intestine of H. polygyrus-infected, 119 
compared to naïve mice, that were detected in positive ion mode, are reported. m/z= mass to 120 
charge ratio, rt= column retention time, fold= fold change. Putative identities (IDs) were 121 
assigned to each metabolite feature where possible. 122 
 123 
m/z rt fold Putative ID (s) Formula Class 
438.29793 18.34 2179.6 PE(P-16:0/0:0) C21H44NO6P 
Glycerophosphoethanol-
amines 
566.31331 11.42 33.6 Unknown - - 
634.53196 17.86 14.9 Unknown - - 
516.34229 14.21 13.4 
PC(P-17:0/0:0) or 
PE(P-20:0/0:0) C25H52NO6P 
Glycerophosphocholines or 
Glycerophosphoethanol-
amines 
451.30583 11.82 12.8 
Methyl diacetoxy-10-
gingerdiol C26H42O6 - 
566.45479 15.2 11.3 Multiple C30H64NO6P Glycerophosphocholines 
359.21907 9.21 11.2 Multiple C20H32O4 Eicosanoids  
490.3273 12.92 11.1 Multiple C23H50NO6P 
Glycerophosphocholines or 
Glycerophosphoethanol-
amines 
445.2043 4.87 9.9 Multiple C19H34O10 Fatty Acyl Glycosides 
 25 
514.32658 13.17 9.1 Unknown - - 
468.34489 12.92 8.8 Multiple C23H50NO6P 
Glycerophosphocholines or 
Glycerophosphoethanol-
amines 
950.73035 20.62 8.3 Unknown - - 
683.48392 18.66 6.9 Unknown - - 
306.27896 10.3 6.8 Clavepictine B C20H35NO Sphingoid Bases 
359.17209 10.39 5.3 Multiple C21H24N2O2 Alkaloids 
705.5916 17.35 5.1 SM(d18:0/16:0) C39H81N2O6P Phosphosphingolipids 
316.23403 18.65 4.6 Unknown - - 
480.3221 10.4 3.3 Unknown - - 
293.17882 12.38 2.6 Unknown - - 
385.17837 12.3 2.5 
17,21-Epoxy-9-fluoro-
11beta-hydroxypregn-
4-ene-3,20-dione C21H27FO4 - 
318.22772 12.38 2.5 Unknown - - 
311.18935 12.38 2.4 Unknown - - 
334.20539 12.38 2.3 Unknown - - 
627.43465 12.87 2.3 Unknown - - 
353.21115 12.38 2.2 
Methyl (9Z)-8'-oxo-
6,8'-diapo-6-
carotenoate C23H28O3 Diterpenoids 
 124 
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Supplementary Table 4. Putative identities of metabolites detected in negative ion mode 126 
upregulated in the small intestine of H. polygyrus-infected compared with uninfected mice. 127 
Untargeted UPLC-FTMS was performed to identify the differential abundance of metabolites in 128 
the small intestine of naïve or day 14 H. polygyrus-infected 129S1/SvImJ mice. Those 129 
metabolites significantly upregulated (p= <0.01) in the small intestine of H. polygyrus-infected, 130 
compared to naïve mice, that were detected in negative ion mode, are reported. m/z= mass to 131 
charge ratio, rt= column retention time, fold= fold change. Putative identities (IDs) were 132 
assigned to each metabolite feature where possible. 133 
 134 
m/z rt fold Putative ID (s) Formula Class 
636.46473 15.23 26.8 Unknown - - 
606.41807 13.32 25.2 Unknown - - 
608.43343 14.17 21.3 Unknown - - 
467.21569 4.87 12.5 Unknown - - 
403.21211 9.23 12.2 Multiple C23H32O6 Steroids or Isoprenoids 
335.22439 9.23 10.4 Unknown - - 
582.41743 14.05 10.3 Unknown - - 
421.21007 4.87 9.6 Unknown - - 
560.33638 14.21 8.9 
PC(18:2(9Z,12Z)/2:0)[
U] C28H52NO8P Glycerophosphocholines 
466.33247 12.93 8.9 Unknown - - 
516.32559 11.42 7.7 Unknown - - 
329.12963 10.43 5.2 Unknown - - 
582.38093 11.72 4.5 Unknown - - 
363.21707 11.01 3.8 Multiple C21H32O5 Steroids 
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223.17117 10.22 3.1 Unknown - - 
323.26074 12.33 2.5 Unknown - - 
 135 
